Industry
Biotechnology
CervoMed Inc., a clinical-stage biotechnology company, engages in the development and commercialization of drug treatments for neurodegenerative diseases. It develops neflamapimod, an orally administered small molecule brain penetrant for the treatment of dementia with Lewy bodies (DLB), Alzheimer's diseases, and brain stroke recovery. The company is based in Boston, Massachusetts.
Loading...
Open
10.99
Mkt cap
89M
Volume
67K
High
11.29
P/E Ratio
4.66
52-wk high
26.38
Low
10.46
Div yield
N/A
52-wk low
5.85
Portfolio Pulse from Benzinga Newsdesk
June 11, 2024 | 12:27 pm
Portfolio Pulse from Benzinga Newsdesk
May 29, 2024 | 10:38 am
Portfolio Pulse from Avi Kapoor
May 20, 2024 | 5:28 pm
Portfolio Pulse from Benzinga Newsdesk
May 20, 2024 | 12:04 pm
Portfolio Pulse from Benzinga Newsdesk
May 15, 2024 | 12:14 pm
Portfolio Pulse from Avi Kapoor
April 08, 2024 | 12:00 pm
Portfolio Pulse from Benzinga Newsdesk
April 08, 2024 | 11:38 am
Portfolio Pulse from Benzinga Newsdesk
March 28, 2024 | 12:48 pm
Portfolio Pulse from Benzinga Newsdesk
March 28, 2024 | 12:35 pm
Portfolio Pulse from Benzinga Insights
March 21, 2024 | 5:31 pm
All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.